Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

849
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
849
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

769
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
769
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiota Therapy: Ready for Clinical Practice?

Visceral medicine·2024
Same author

Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study.

Journal of gastrointestinal and liver diseases : JGLD·2023
Same author

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.

Journal of Crohn's & colitis·2023
Same author

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines.

Annals of gastroenterology·2023
Same author

[Microbiome: from pathophysiology to clinical application?]

Deutsche medizinische Wochenschrift (1946)·2023
Same author

Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition.

Clinical nutrition (Edinburgh, Scotland)·2023

Related Experiment Video

Updated: Feb 26, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Fistulizing Crohn's Disease.

Michael Scharl1, Gerhard Rogler1, Luc Biedermann1

  • 1Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Clinical and Translational Gastroenterology
|July 14, 2017
PubMed
Summary
This summary is machine-generated.

Crohn

More Related Videos

Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

17.5K
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

920

Related Experiment Videos

Last Updated: Feb 26, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K
Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

17.5K
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

920

Area of Science:

  • Gastroenterology and Immunology
  • Cell Biology
  • Microbiome Research

Background:

  • Fistulas are a significant complication in Crohn's disease (CD), affecting at least one-third of patients.
  • Long-term remission of complex fistulas is achieved in only about one-third of affected individuals.
  • The precise pathogenesis of fistula development in CD remains incompletely understood.

Purpose of the Study:

  • To review the current understanding of fistula pathogenesis in Crohn's disease.
  • To discuss diagnostic methods and current treatment strategies for fistulas.
  • To explore emerging therapeutic approaches for Crohn's disease fistulas.

Main Methods:

  • Literature review of fistula pathogenesis, diagnosis, and treatment in Crohn's disease.
  • Analysis of histopathological findings, molecular pathways (e.g., epithelial-to-mesenchymal transition), and inflammatory markers (TNF, IL-13, TGFβ).
  • Evaluation of diagnostic modalities including clinical assessment, imaging (MRI), and endoscopy.

Main Results:

  • Epithelial-to-mesenchymal transition (EMT) is implicated as a driving force in fistula development.
  • Elevated levels of TNF, IL-13, and TGFβ are observed around fistulas, with a potential role for intestinal microbiota.
  • Current treatments include antibiotics, immunosuppressives, and anti-TNF agents, but efficacy is often limited, necessitating surgery.

Conclusions:

  • Fistula management in Crohn's disease requires a comprehensive approach combining diagnosis and treatment.
  • Novel therapies, such as mesenchymal stem cells, show promise but require further investigation.
  • Continued research into fistula pathogenesis is crucial for developing more effective treatments and improving patient outcomes.